Drug discovery · Rare inherited metabolic disease
Perlara PBC
The first biotech incorporated as a public benefit corporation. It ran out of money in 2019, came back as a distributed yeast lab paid for by rare disease families, and now runs on a federal grant. Its lead clinical program was stopped for futility.
The post
On February 28, 2019, the chief executive of a small South San Francisco biotech went on social media and told everyone the company was finished.
“The science was working and although from the outside it looked like the business was working the PerlQuest model had an Achilles heel painfully revealed when an early backer and partner bailed on a licensing deal after months of negotiations, triggering a fatal tail spin,” Ethan Perlstein wrote in a Facebook post reported by Global Genes. “We scrambled and schemed to do everything we could to salvage operations.”
Five years earlier he had incorporated it as a public benefit corporation, a for profit structure that obliges directors to weigh a stated mission alongside returns. He had put the letters in the legal name and blogged the spending.
Now the money was gone. Business Insider counted nearly $10 million raised from investors, about $2 million of research revenue from patient groups, and 15 staff at the peak. Perlstein told the reporter the model had been real: “It was tenuous, not fully sustainable. But it was working.”
Why a yeast cell
Inherited metabolic diseases are individually tiny and collectively large. Most trace to a single broken gene, most show up in childhood, and almost none have an approved therapy. Nobody builds a program around a few hundred patients.
Perlara's answer was to skip the target and go straight to the organism. Engineer the patient's exact mutation into budding yeast, or a worm, or a fly. The mutant grows badly. Then wash thousands of approved drugs across the sick cells and see which ones fix the growth defect. A hit is something a doctor can already prescribe.
The company sold that work to families directly, in staged projects it called PerlQuests, paid in tranches by a foundation or a parent. Its first deal was with Novartis. Almost every one after that was with a patient group.
The founder who quit academia in public
Perlstein took a PhD at Harvard in Stuart Schreiber's lab and did an independent postdoctoral fellowship at Princeton's Lewis-Sigler Institute from 2007 to 2012. He then left the tenure track loudly, on Twitter, arguing that the system was training more scientists than it could absorb.
The same account later brought him a billionaire. In August 2017 Mark Cuban read a tweet about drug pricing and asked for the pitch deck. Cuban's Radical Investments put $250,000 into a $7.4 million round, then funded a separate program on Leigh syndrome.
The board reflected the customer base rather than the capital markets. The 2017 Form D lists two outside directors: Matthew Wilsey, whose daughter Grace has NGLY1 deficiency and who runs the Grace Science Foundation, and Linda Avey, a co-founder of 23andMe.
What came back
After the shutdown Perlstein spent a year at the Christopher and Dana Reeve Foundation as its first chief scientific officer. COVID ended that. By late 2021 he had restarted the company with no lab of its own, renting bench time and hiring part time scientists it called Cure Guides. An a16z publication in 2022 described the new Perlara as running “with a team of decentralized scientist-consultants who work collaboratively to write roadmaps for patient families and foundations searching for cures.”
One asset survived the collapse and became the proof point. A yeast screen run for a Michigan family had turned up epalrestat, an aldose reductase inhibitor sold in Japan for diabetic neuropathy. Their daughter took it under compassionate use. In August 2020 Perlara, the family's foundation Maggie's Cure, and Mayo Clinic formed a joint venture called Maggie's Pearl. The FDA cleared a Phase 3 trial in December 2021. The trial started at Mayo Clinic in Rochester on November 10, 2022.
That trial is now over. The registry record, updated on September 22, 2025, lists it as terminated. The reason given is three words: due to futility.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Phase 3 epalrestat trial | NCT04925960, sponsor Maggie's Pearl LLC, one site at Mayo Clinic Rochester, PI Eva Morava-Kozicz. Started Nov 10, 2022. Actual enrollment 42. Status terminated, reason “Due to futility.” Primary completion and study completion both Feb 28, 2025. Last update posted Sep 25, 2025. No results posted. | Public record |
| The same trial, as presented today | The Perlara website calls it the flagship and cites a 38 patient Phase III reached in under three years for less than $5M, with no mention of the termination. The Maggie's Pearl science page still says a trial is being conducted. | Differs from the registry |
| Federal grant | NIH SBIR Direct to Phase II, R44GM161192, project REMIT, administered by NIGMS. Award notice Sep 10, 2025, project start Sep 12, 2025, end Aug 31, 2027. $1,016,229 in FY2025 and $692,113 in FY2026. PI Ethan Perlstein, Perlara PBC, Alameda, CA. | Public record |
| How the grant is described | The website dates the award to November 2025 and credits NIH NCATS. The record names NIGMS and dates the notice to Sep 10, 2025. The $1.7 million total matches. | Differs from the record |
| Peer reviewed output | Perlstein is an author across all three eras: G3 and two Disease Models and Mechanisms papers in 2019, eLife 2022, Glycobiology 2024, a 2025 review in the Journal of Inherited Metabolic Disease, and a Communications Biology paper in January 2026. | Public record |
| Platform paper | The paper describing the industrialized yeast platform is a bioRxiv preprint from August 2024. A second, on atorvastatin for SRD5A3-CDG, posted January 2026. Neither is peer reviewed. | Preprint only |
| Platform throughput | 34 yeast models and 8,384 compounds profiled, counters on the company home page. In 2023 it reported six of twelve SURF1 yeast hits bioactive in patient fibroblasts. Not independently replicated in public. | Company-stated |
| Foundation partnerships | Named partners include Maggie's Cure, Cure Mito Foundation for SURF1 Leigh syndrome, Moonshots for Unicorns for PGAP3-CDG, the PIGN-CDG Cure Collective, the FAM177A1 Research Fund, and earlier, Mission: Cure. Amounts undisclosed. | Company-stated |
| Regulatory record of its own | No FDA 510(k), no PMA, and no trial registered with Perlara PBC as sponsor. | Not found |
Read plainly: the discovery engine is real and documented across three separate eras of the company. What the record does not contain is a drug that worked in a controlled trial. The one program that got that far returned a futility call, and the public materials have not been updated to say so. That gap matters here, because the families paying for these programs are the ones reading the website.
What to watch
- Results for NCT04925960. The trial completed in February 2025 and nothing has been posted.
- Whether Maggie's Pearl continues in any form, and what PMM2-CDG families are told next.
- The REMIT grant, which runs to August 31, 2027. Year two was obligated in August 2026.
- A second clinical asset. The model only works if a yeast hit reaches a trial more than once.
In their words
“It sounds crazy, but Perlara felt like the closest thing to having a child with a rare disease.”
Ethan Perlstein, 2019 wind down post, reported by Global Genes · Independent
“Be as idealistic as your heart wants you to be, but know with your brain to make a business, you're going to have to sacrifice one of those dimensions.”
Ethan Perlstein to Business Insider, 2019 · Independent
“But once you're in it, every day there's a new fire; every week, there's maybe one thing to celebrate that gets you through.”
Ethan Perlstein to Chemical & Engineering News, 2018 · Independent
“Ultimately, the only way to make this repeatable is to prove that I can get into the clinic multiple times with multiple modalities.”
Ethan Perlstein to BioPharma Dive, 2022 · Interview
“Families affected by rare disease are ready to move mountains, but they lack the financial resources to do so.”
Mark Cuban, Radical Investments, quoted by CNBC, 2018 · Independent
“We can't thank participating families enough. They are medical pioneers and an example for all rare disease communities of what is possible despite the hardships of a placebo-controlled study.”
Ethan Perlstein, CEO of Maggie's Pearl, March 2024 release · Company release
“We went from a single child on compassionate-use epalrestat to a registrational trial in three years on less than $5M in patient-foundation capital. This is what community medicine looks like.”
Perlara website, accessed September 2026 · Company-stated
Related companies
Sources
- Public recordClinicalTrials.gov NCT04925960
- Public recordNIH RePORTER, R44GM161192, REMIT
- Public recordForm D, Perlara PBC
- Public recordForm D, Perlstein Lab PBC
- Public recordPubMed records for Ethan O. Perlstein, 2018 to 2026
- Public recordIndustrializing yeast as a drug repurposing platform
- Public recordRepurposing atorvastatin for SRD5A3-CDG
- IndependentPerlara to wind down operations
- IndependentAfter his biotech startup fails, a CEO reflects on what went wrong
- IndependentIts founder shares the key lesson from the failure
- IndependentA rare-disease entrepreneur takes an unconventional path
- IndependentTweet leads Mark Cuban to invest in Perlara
- IndependentMark Cuban invests in tiny Bay Area biotech Perlara
- InterviewPerlstein on reviving a biotech
- IndependentA guide to decentralized biotech
- IndependentBoard of Fellows, naming two Perlara directors
- CompanyPerlara home and About pages
- CompanyPerlara 1.0 archive site
- CompanyCure Odysseys notebook
- PartnerMaggie's Pearl initiates Phase III trial
- PartnerPhase III trial crosses over to open label
- CompanyPerlara profile
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
